Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $5
Esperion Therapeutics Is Maintained at Neutral by Goldman Sachs
Esperion Therapeutics Analyst Ratings
Goldman Sachs Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Cuts Target Price to $3
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $5
Esperion Therapeutics Price Target Maintained With a $5.00/Share by Needham
JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
Esperion Therapeutics Analyst Ratings
Esperion Therapeutics Price Target Maintained With a $4.00/Share by Citizens Capital Markets
JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $4
JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $4
Needham Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Cuts Target Price to $5
Esperion Therapeutics Analyst Ratings
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
Esperion Therapeutics Analyst Ratings
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
JMP Securities Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Cuts Target Price to $4
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $2.05 to $16